Amaravadi, Ravi K.

Guidelines for the use and interpretation of assays for monitoring autophagy

Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 3,996

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,434

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 2,156

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,664

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 1,646

Autophagy in major human diseases

Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal

Autophagy in Disease and TherapyUbiquitin and proteasome pathways

Cited by 1,585

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 1,216

Autophagy in malignant transformation and cancer progression

Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal

Autophagy in Disease and TherapyUbiquitin and proteasome pathways

Cited by 1,182

Targeting Autophagy in Cancer: Recent Advances and Future Directions

Amaravadi, R. K., Kimmelman, A. C., & Debnath, J. (2019) · Cancer Discovery

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 928

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 457

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 367

Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome

Lazova, R., Camp, R. L., Klump, V., Siddiqui, S. F., Amaravadi, R. K., & Pawelek, J. M. (2012) · Clinical Cancer Research

Autophagy in Disease and TherapyCancer, Hypoxia, and Metabolism

Cited by 305

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 255

Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma

Ma, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K. (2011) · Clinical Cancer Research

Autophagy in Disease and TherapyCutaneous Melanoma Detection and Management

Cited by 234

A randomized Phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine/nab-paclitaxel in pancreatic cancer patients

Zeh, H. J., Bahary, N., Boone, B. A., Singhi, A. D., Miller-Ocuin, J. L., Normolle, D. P., Zureikat, A. H., Hogg, M. E., Bartlett, D. L., Lee, K. K., et al. (2020) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchAutophagy in Disease and Therapy

Cited by 233

Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy

Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A., & O'Dwyer, P. J. (2013) · Clinical Cancer Research

Autophagy in Disease and TherapyCancer, Hypoxia, and Metabolism

Cited by 221

Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells

Hubbard-Lucey, V. M., Shono, Y., Maurer, K., West, M. L., Singer, N. V., Ziegler, C. G. K., Lezcano, C., Motta, A. C. F., Schmid, K., Levi, S. M., et al. (2014) · Immunity

Autophagy in Disease and TherapyT-cell and B-cell Immunology

Cited by 102

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

Sharma, G., Ojha, R., Noguera-Ortega, E., Rebecca, V. W., Attanasio, J., Liu, S., Piao, S., Lee, J. J., Nicastri, M. C., Harper, S. L., et al. (2020) · JCI Insight

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 80

Inhibition of autophagy enhances the effects of the AKT inhibitor MK‐2206 when combined with paclitaxel and carboplatin in BRAF wild‐type melanoma

Rebecca, V. W., Massaro, R. R., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., Kim, E., Amaravadi, R. K., Maria‐Engler, S. S., Messina, J. L., Gibney, G. T., et al. (2014) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 58

miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Liu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., Krepler, C., Xiao, M., Beqiri, M., Xu, W., et al. (2015) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysMicroRNA in disease regulation

Cited by 54

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial

Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., et al. (2019) · Retina

Drug-Induced Ocular ToxicityOcular Oncology and Treatments

Cited by 31